Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

NCT05733689 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Gastroesophageal Adenocarcinoma

Interventions

COMBINATION_PRODUCT: FLOT
COMBINATION_PRODUCT: FOLFOX
COMBINATION_PRODUCT: FOLFIRI
COMBINATION_PRODUCT: FOLFIRINOX
COMBINATION_PRODUCT: PACLITAXEL with or without CARBOPLATIN
COMBINATION_PRODUCT: DOCETAXEL and IRINOTECAN (alone or combined)
DRUG: NIVOLUMAB (alone or when added to a regimen above)
DRUG: PEMBROLIZUMAB (alone or when added to a regimen above)
DRUG: Durvalumab
DRUG: Trastuzumab

Sponsor

University of California, Irvine

Collaborators

[object Object]